437 related articles for article (PubMed ID: 26042842)
1. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis.
Lambert AA; Lam JO; Paik JJ; Ugarte-Gil C; Drummond MB; Crowell TA
PLoS One; 2015; 10(6):e0128004. PubMed ID: 26042842
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of proton pump inhibitors induced risk of community-acquired pneumonia.
Nguyen PA; Islam M; Galvin CJ; Chang CC; An SY; Yang HC; Huang CW; Li YJ; Iqbal U
Int J Qual Health Care; 2020 Jun; 32(5):292-299. PubMed ID: 32436582
[TBL] [Abstract][Full Text] [Related]
3. Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis.
Giuliano C; Wilhelm SM; Kale-Pradhan PB
Expert Rev Clin Pharmacol; 2012 May; 5(3):337-44. PubMed ID: 22697595
[TBL] [Abstract][Full Text] [Related]
4. Proton Pump Inhibitors and the Risk of Community-Acquired Pneumonia: An Updated Meta-analysis.
Xun X; Yin Q; Fu Y; He X; Dong Z
Ann Pharmacother; 2022 May; 56(5):524-532. PubMed ID: 34425689
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitor therapy predisposes to community-acquired Streptococcus pneumoniae pneumonia.
de Jager CP; Wever PC; Gemen EF; van Oijen MG; van Gageldonk-Lafeber AB; Siersema PD; Kusters GC; Laheij RJ
Aliment Pharmacol Ther; 2012 Nov; 36(10):941-9. PubMed ID: 23034135
[TBL] [Abstract][Full Text] [Related]
6. Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed.
Hermos JA; Young MM; Fonda JR; Gagnon DR; Fiore LD; Lawler EV
Clin Infect Dis; 2012 Jan; 54(1):33-42. PubMed ID: 22100573
[TBL] [Abstract][Full Text] [Related]
7. Proton-pump inhibitor use and the risk for community-acquired pneumonia.
Sarkar M; Hennessy S; Yang YX
Ann Intern Med; 2008 Sep; 149(6):391-8. PubMed ID: 18794558
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy and the risk for community-acquired pneumonia.
Gau JT; Acharya U; Khan S; Heh V; Mody L; Kao TC
BMC Geriatr; 2010 Jul; 10():45. PubMed ID: 20604960
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. Confounding in the association of proton pump inhibitor use with risk of community-acquired pneumonia.
Jena AB; Sun E; Goldman DP
J Gen Intern Med; 2013 Feb; 28(2):223-30. PubMed ID: 22956446
[TBL] [Abstract][Full Text] [Related]
11. Meta-analysis: proton pump inhibitor use and the risk of community-acquired pneumonia.
Johnstone J; Nerenberg K; Loeb M
Aliment Pharmacol Ther; 2010 Jun; 31(11):1165-77. PubMed ID: 20222914
[TBL] [Abstract][Full Text] [Related]
12. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis.
Filion KB; Chateau D; Targownik LE; Gershon A; Durand M; Tamim H; Teare GF; Ravani P; Ernst P; Dormuth CR;
Gut; 2014 Apr; 63(4):552-8. PubMed ID: 23856153
[TBL] [Abstract][Full Text] [Related]
13. What is the long term acid inhibitor treatment in gastroesophageal reflux disease? What are the potential problems related to long term acid inhibitor treatment in gastroesophageal reflux disease? How should these cases be followed?
Hatemi İ; Esatoğlu SN
Turk J Gastroenterol; 2017 Dec; 28(Suppl 1):S57-S60. PubMed ID: 29199170
[TBL] [Abstract][Full Text] [Related]
14. Drugs that increase the risk of community-acquired pneumonia: a narrative review.
Liapikou A; Cilloniz C; Torres A
Expert Opin Drug Saf; 2018 Oct; 17(10):991-1003. PubMed ID: 30196729
[TBL] [Abstract][Full Text] [Related]
15. Common medications that increase the risk for developing community-acquired pneumonia.
Restrepo MI; Mortensen EM; Anzueto A
Curr Opin Infect Dis; 2010 Apr; 23(2):145-51. PubMed ID: 20075727
[TBL] [Abstract][Full Text] [Related]
16. Optimum duration of regimens for Helicobacter pylori eradication.
Yuan Y; Ford AC; Khan KJ; Gisbert JP; Forman D; Leontiadis GI; Tse F; Calvet X; Fallone C; Fischbach L; Oderda G; Bazzoli F; Moayyedi P
Cochrane Database Syst Rev; 2013 Dec; (12):CD008337. PubMed ID: 24338763
[TBL] [Abstract][Full Text] [Related]
17. Microbial evaluation of proton-pump inhibitors and the risk of pneumonia.
Meijvis SC; Cornips MC; Voorn GP; Souverein PC; Endeman H; Biesma DH; Leufkens HG; van de Garde EM
Eur Respir J; 2011 Nov; 38(5):1165-72. PubMed ID: 21478217
[TBL] [Abstract][Full Text] [Related]
18. Community acquired pneumonia incidence before and after proton pump inhibitor prescription: population based study.
Othman F; Crooks CJ; Card TR
BMJ; 2016 Nov; 355():i5813. PubMed ID: 28715344
[No Abstract] [Full Text] [Related]
19. Proton-Pump Inhibitors and Long-Term Risk of Community-Acquired Pneumonia in Older Adults.
Zirk-Sadowski J; Masoli JA; Delgado J; Hamilton W; Strain WD; Henley W; Melzer D; Ble A
J Am Geriatr Soc; 2018 Jul; 66(7):1332-1338. PubMed ID: 29676433
[TBL] [Abstract][Full Text] [Related]
20. The Risk of Community-Acquired Enteric Infection in Proton Pump Inhibitor Therapy: Systematic Review and Meta-analysis.
Hafiz RA; Wong C; Paynter S; David M; Peeters G
Ann Pharmacother; 2018 Jul; 52(7):613-622. PubMed ID: 29457492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
